American Heart Association Scientific Sessions 2019
ODYSSEY OUTCOMES: alirocumab benefits in older patients
In patients with recent ACS, alirocumab improves outcomes irrespective of age. Increasing treatment benefit but not harm with advancing age suggests that marked LDL-C lowering is an important secondary preventive intervention for older patients. Previously, the ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to…
read more »
LIB003: open label extension phase 2B study shows promise
LIB003, a novel recombinant fusion protein therapeutic agent consisting of a PCSK9-binding domain (adnectin) and human serum albumin, provides maximal stable mean reductions of LDL-C of nearly 60% from baseline in high-risk patients with hypercholesterolaemia and was well tolerated. Dr Evan Stein (LIB Therapeutics and…
read more »
Alirocumab shows benefit post-MI
A Japanese research group showed that treatment with alirocumab reduces LDL-C, a highly atherogenic molecule (LOX-1) and N-terminal pro-brain natriuretic peptide (NT-pro BNP) in a small study of patients following acute myocardial infarction.1 The acute effects of PCSK9 inhibitors on MI patients has not previously…
read more »
ODYSSEY OUTCOMES: alirocumab reduces total hospitalisations, increases DAOH
New patient-centred outcomes data from the ODYSSEY OUTCOMES trial* (NCT01663402) in patients with acute coronary syndrome (ACS) shows that alirocumab compared with placebo reduced total hospitalisations, increased days alive and out of hospital (DAOH) and increased the likelihood of survival without hospitalisation. Over a median…
read more »
FOURIER: effects of evolocumab on cognition and following MI
Two new analyses from the FOURIER trial have provided further information on the impact of evolocumab on patients’ every day cognition and on cardiovascular outcomes following a recent myocardial infarction (MI). The FOURIER study randomized 27,564 pts with stable atherosclerotic cardiovascular disease (ASCVD) treated with…
read more »
ORION-9: durable and potent LDL-C lowering in HeFH patients on twice-yearly dosing
Results presented at AHA 2019 demonstrated that twice-yearly inclisiran reduced LDL-C by 50% in patients with heterozygous familial hypercholesterolaemia (HeFH). The ORION-9 study (NCT03397121) met all its primary and secondary efficacy endpoints and 50% LDL-C lowering was observed at day 510 (p<0.0001) with a 45%…
read more »
ORION-10: effective LDL-C lowering in patients with ASCVD with twice yearly dosing
In the ORION-10 trial (NCTNCT03399370) twice-yearly inclisiran safely reduced LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) with continued high LDL-C despite being on maximum tolerated statin dose. Full study results were presented during a late-breaking science session at the American Heart Association (AHA) Scientific…
read more »
